Volume 7, Number 1—February 2001
High-Level Ciprofloxacin Resistance in Neisseria gonorrhoeae: First Report from Israel
Highlight and copy the desired format.
|EID||Dan M, Poch F, Shpitz D, Sheinberg B. High-Level Ciprofloxacin Resistance in Neisseria gonorrhoeae: First Report from Israel. Emerg Infect Dis. 2001;7(1):158-159. https://dx.doi.org/10.3201/eid0701.700158|
|AMA||Dan M, Poch F, Shpitz D, et al. High-Level Ciprofloxacin Resistance in Neisseria gonorrhoeae: First Report from Israel. Emerging Infectious Diseases. 2001;7(1):158-159. doi:10.3201/eid0701.700158.|
|APA||Dan, M., Poch, F., Shpitz, D., & Sheinberg, B. (2001). High-Level Ciprofloxacin Resistance in Neisseria gonorrhoeae: First Report from Israel. Emerging Infectious Diseases, 7(1), 158-159. https://dx.doi.org/10.3201/eid0701.700158.|
To the Editor: We report a case of male gonococcal urethritis that persisted despite ciprofloxacin therapy. The isolate was found to be highly resistant (MIC 32 µg/mL).
A 30-year-old man visited his family physician with a 2-day history of urethral discharge and dysuria. The symptoms began 7 days after a single, unprotected orogenital contact with a female hitchhiker. The patient denied exchange of money for the act and reported no other recent sex partners or travel outside Israel. After a urethral swab was obtained for culture, the patient received a single dose of ciprofloxacin (500 mg orally). Growth of Neisseria gonorrhoeae was subsequently reported. However, symptoms persisted, and a regimen of doxycycline (100 mg orally twice daily for 10 days) was initiated. After temporary clinical improvement, the patient returned with worsening symptoms: bloody urethral discharge, severe dysuria, edema of the penis, and painful erection. N. gonorrhoeae was reisolated from a repeat urethral swab. When a single dose of ceftriaxone (250 mg) was administered intramuscularly, clinical cure was prompt.
Susceptibility testing was performed on the second isolate by using the E-test method (AB Biodisk, Solna, Sweden) on a medium containing GC agar base and 1% defined growth supplement. The MIC of ciprofloxacin was 32 µg/mL, penicillin 1.5 µg/mL, tetracycline 2 µg/mL, and ceftriaxone 0.016 µg/mL. The isolate did not produce beta-lactamase. It was classified as a CMRNGPT phenotype (N. gonorrhoeae with chronomosomally mediated resistance to both penicillin and tetracycline).
Gonorrhea was considered a rare disease in Israel in the 1990s: the average annual incidence was 0.89 reported cases per 100,000 population (1). Most laboratories did not carry appropriate media, and susceptibility testing of N. gonorrhoeae was not performed routinely. Quinolones and spectinomycin are the antibiotics most commonly used to treat the infection. Nevertheless, we are not aware of any instance of clinical failure following fluoroquinolone therapy. More recently, however, the incidence of gonorrhea has been increasing (2). In response, a surveillance program for monitoring antimicrobial resistance in N. gonorrhoeae has been launched.
Fluoroquinolones and cephalosporins became the recommended drugs for treatment of gonococcal infection after penicillin- and tetracycline-resistant N. gonorrhoeae appeared (3). Gonococcal strains with reduced in vitro susceptibility to fluoroquinolones (MIC, 0.125 µg/mL to 0.5 µg/mL) were first described in the mid-1980s (4) and are now occurring worldwide (5).
Fluoroquinolone-resistant N. gonorrhoeae (ciprofloxacin MIC >1.0 µg/mL) emerged during the 1990s and became well established in several Asian countries (6). In Japan, the rate of ciprofloxacin resistance increased from 6.6% in 1993-1994 to 24.4% in 1997-1998 (7). More recently, high-level resistance to ciprofloxacin and reports of treatment failure have appeared (8). Strains with ciprofloxacin MICs of >8.0 µg/mL were first isolated in 1994 (6) and are detected mostly in the Far East. Two cases of gonococcal infection by strains with an MIC of 16 µg/mL were recently reported in the United States (9). Gonococcal resistance to fluoroquinolones is associated with mutations in the genes encoding DNA gyrase (gyrA) and topoisomerase (parC) as well as change in porin permeability and reduced intracellular drug accumulation (6). In view of the increasing resistance to fluoroquinolones, ceftriaxone, cefixime, or spectinomycin is now recommended if an infection was acquired in Asia or other areas with known fluoroquinolone resistance (9).
Our patient reported no travel to the Far East, and his sex partner, who could not be located for follow-up, was not Asian; her travel history was unknown. The mode of transmission of this infection was fellatio. Condoms are often not used in this form of intercourse, even by those who regularly use condoms for genito-genital sex, because of the mistaken belief that infection is not spread through this form of intercourse. It is now well established that oral sex plays an important role in HIV transmission (10), and condoms should be used with any form of intimate sexual contact.
- The Israel Center for Diseases Control. Notifiable infectious disease in Israel, 1951-1995. Israel: State of Israel Ministry of Health; 1996. Publication No. 201.
- Report on emerging issues, July-December 1999. Tel-Aviv, Israil: District Health Office, State of Israel Ministry of Health; Jan 10, 2000.
- Centers for Disease Control and Prevention. Guidelines for treatment of sexually transmitted diseases. Morb Mortal Wkly Rep. 1998;47(PR-1):1–116.
- Tapsall JW, Shultz TR, Phillips EA. Characteristics of Neisseria gonorrhoeae isolated in Australia showing decreased sensitivity to quinolone antibiotics. Pathology. 1992;24:27–31.
- Quinn TC. The impact of antimicrobial resistance on the treatment of sexually transmitted diseases. Infect Dis Clin North Am. 1997;11:884–904.
- Knapp JS, Fox KK, Trees DL, Whittington WL. Fluoroquinolone resistance in Neisseria gonorrhoeae. Emerg Infect Dis. 1997;3:33–8.
- Tanaka M, Nakayama H, Haraoka M, Saika T, Kobayashi I, Naito S. Antimicrobial resistance of Neisseria gonorrhoeae and high prevalence of ciprofloxacin-resistant isolates in Japan, 1993 to 1998. J Clin Microbiol. 2000;38:521–5.
- Tapsall JW, Limnios EA, Thacker C, Donovan B, Lynch SD, Kirky LJ, High-level quinolone resistance in Neisseria gonorrhoeae: a report of two cases. Sex Transm Dis. 1995;22:310–1.
- Centers for Disease Control and Prevention. Fluoroquinolone-resistant Neisseria gonorrhoeae-San Diego, California, 1997. Morb Mortal Wkly Rep. 1998;47:405–8.
- Dillon B, Hecht FM, Swanson M, Goupil-Sormany I, Grant RH, Chesney MA, Primary HIV infections associated with oral transmission. Presented at the 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, Jan 30-Feb 2, 2000 (Abstract 473).
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
- Page created: March 17, 2011
- Page last updated: March 17, 2011
- Page last reviewed: March 17, 2011
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)